- Novo Nordisk completed the acquisition of Akero for $4.7 billion.
- An additional $0.5 billion is contingent on EFX's US regulatory approval.
- Akero is now a wholly owned subsidiary of Novo Nordisk.
- Akero's stock is no longer listed on Nasdaq.
Acquisition Completion
Novo Nordisk has finalized its acquisition of Akero Therapeutics, initially announced on October 9, 2025. The transaction involved purchasing all outstanding shares of Akero for $54 per share, totaling an aggregate value of $4.7 billion.
Contingent Value Right
As part of the deal, a non-transferable Contingent Value Right (CVR) was included. This CVR entitles holders to an additional $6 per share, amounting to $0.5 billion, contingent upon US regulatory approval of Akero's lead candidate, EFX, for treating compensated cirrhosis due to MASH.
Subsidiary Status
Following the acquisition, Akero has become a wholly owned subsidiary of Novo Nordisk. Consequently, Akero's common stock will no longer be listed or traded on the Nasdaq Global Select Market.
Akero's Focus
Akero Therapeutics is a clinical-stage company focused on developing treatments for serious metabolic diseases, including metabolic dysfunction-associated steatohepatitis (MASH). Their lead product, efruxifermin (EFX), is under evaluation in three Phase 3 clinical studies targeting different stages of MASH.
